The European Union (EU) complained of the delay in the delivery of the Oxford-AstraZeneca’s new type of coronavirus (Covid-19) vaccine, which it has not yet approved for use.
Stella Kyriakides, member of the EU Commission responsible for health, stated on her social media account that they held a committee meeting with EU member countries representatives on vaccination strategy.
Stating that AstraZeneca representatives announced that there would be delays in vaccine deliveries to the EU in the first quarter of the year, Kyirakides said, “The EU Commission and member countries expressed their dissatisfaction with this situation.” found the assessment.
Kyirakides stated that the EU insists on determining a definite delivery schedule based on the conditional marketing authorization of vaccines, and that the member countries plan their vaccination programs accordingly, “The EU Commission will continue to insist on measures that will increase the predictability and stability of deliveries to AstraZeneca and accelerate dose distribution. . ” she used her expressions.
Application was made to EMA for vaccine approval
An application was made to the European Medicines Agency (EMA) for the approval of the vaccine that Oxford University developed with the British Swedish pharmaceutical company AstraZeneca. The EU approval of the vaccine was expected to be released at the end of January.
The vaccines developed by BioNTech and Pfizer and Moderna, which have been approved in the EU so far, have been made public since December 2020.
The EU Commission has reached a position to receive approximately 2.3 billion doses with 6 contracts made on behalf of member countries with companies that develop vaccines to date. The EU has signed contracts to purchase 600 million doses of vaccine with BioNTech-Pfizer, 400 million doses with AstraZeneca, 300 million with Sanofi-GSK, 400 million with Johnson and Johnson, 405 million doses with CureVac and 160 million with Moderna, including options. However, there is criticism that vaccination is slow in EU countries.
The EU Commission set a target this week to vaccinate 70 percent of the adult population in member countries by 1 June. As a result of delays in vaccine deliveries, the possibility of not reaching the target increases.